Amicus Therapeutics, Inc. (FOLD) Financial Statements (2024 and earlier)

Company Profile

Business Address 3675 MARKET STREET
PHILADELPHIA, PA 19104
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments293,595482,496483,269452,740504,152358,562
Cash and cash equivalents148,813245,197163,240142,83779,74949,060
Short-term investments144,782237,299320,029309,903424,403309,502
Receivables66,19652,67246,92333,28421,9629,464
Inventory, net of allowances, customer advances and progress billings23,81626,81819,55614,0418,3904,623
Inventory23,81626,81819,55614,0418,3904,623
Other undisclosed current assets40,20934,84829,72120,00816,59219,316
Total current assets:423,816596,834579,469520,073551,096391,965
Noncurrent Assets
Operating lease, right-of-use asset29,53420,58623,29633,315
Property, plant and equipment30,77842,49643,86347,70511,3759,062
Intangible assets, net (including goodwill)220,797220,797220,797220,797220,797220,797
Goodwill197,797197,797197,797197,797197,797197,797
Intangible assets, net (excluding goodwill)23,00023,00023,00023,00023,00023,000
Other noncurrent assets19,24224,42719,09528,3176,6835,200
Total noncurrent assets:300,351308,306307,051330,134238,855235,059
TOTAL ASSETS:724,167905,140886,520850,207789,951627,024
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:93,63698,15396,841120,37380,62553,890
Interest and dividends payable  3,6794,189313
Taxes payable6,15411,1777,300  
Employee-related liabilities24,25823,02527,15621,73119,620
Accounts payable15,41321,51317,06321,7226,6067,867
Accrued liabilities 53,00518,09712,84415,80010,79713,779
Other undisclosed accounts payable and accrued liabilities 25,21828,13132,73244,71637,30212,311
Debt    7,189  
Business combination, contingent consideration, liability 21,41718,9008,900  8,400
Other undisclosed current liabilities23,96528,92223,9351,2505,5007,750
Total current liabilities:139,018145,975129,676128,81286,12570,040
Noncurrent Liabilities
Long-term debt and lease obligation  43,36345,604203,036321,740164,167
Long-term debt, excluding current maturities    149,505321,740164,167
Liabilities, other than long-term debt65,45613,17028,20033,02822,55325,811
Deferred tax liabilities, net 6,465
Deferred income tax liabilities 4,9394,9304,8965,051
Other liabilities8,9396,8016,3795,2962,8532,346
Operating lease, liability51,57843,36345,60453,531
Business combination, contingent consideration, liability  1,43916,92522,68119,70017,000
Other undisclosed noncurrent liabilities396,646395,263396,6608,90616,621 
Total noncurrent liabilities:462,102451,796470,464244,970360,914189,978
Total liabilities:601,120597,771600,140373,782447,039260,018
Equity
Equity, attributable to parent123,047307,369286,380476,425342,912352,850
Common stock2,8152,8082,6502,5981,9421,721
Additional paid in capital2,664,7442,595,4192,308,5782,227,2251,740,0611,400,758
Accumulated other comprehensive income (loss)(12,105)4,9818,2272,82568(2,095)
Accumulated deficit(2,532,490)(2,295,922)(2,045,462)(1,768,610)(1,412,222)(1,063,610)
Warrants and rights outstanding838312,38712,38713,06316,076
Total equity:123,047307,369286,380476,425342,912352,850
Other undisclosed liabilities and equity      14,156
TOTAL LIABILITIES AND EQUITY:724,167905,140886,520850,207789,951627,024

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues329,233305,514260,886182,23791,24536,930
Revenue, net36,930
Cost of revenue
(Cost of Goods and Services Sold)
(38,599)(34,466)(31,044)(21,963)(14,404)(6,236)
Gross profit:290,634271,048229,842160,27476,84130,694
Operating expenses(502,754)(477,482)(476,840)(464,311)(405,618)(472,679)
Operating loss:(212,120)(206,434)(246,998)(304,037)(328,777)(441,985)
Nonoperating income (expense)7,200(2,392)2,4457,6232,09010,104
Investment income, nonoperating3,0245093,22610,24910,4614,096
Loss, foreign currency transaction, before tax     (2,739) 
Other nonoperating income (expense)4,176(2,901)(781)(2,626)(5,632)6,008
Interest and debt expense(37,119)(32,728)(29,701)(59,496)(22,402)(17,240)
Loss from continuing operations before income taxes:(242,039)(241,554)(274,254)(355,910)(349,089)(449,121)
Income tax expense (benefit)5,471(8,906)(2,598)(478)94165,119
Loss from continuing operations:(236,568)(250,460)(276,852)(356,388)(348,995)(284,002)
Loss before gain (loss) on sale of properties:(250,460)(276,852)(356,388)(348,995)(284,002)
Net loss available to common stockholders, diluted:(236,568)(250,460)(276,852)(356,388)(348,995)(284,002)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(236,568)(250,460)(276,852)(356,388)(348,995)(284,002)
Other comprehensive income (loss)   50(182)  
Comprehensive loss:(236,568)(250,460)(276,802)(356,570)(348,995)(284,002)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(17,086)(3,246)5,3522,9392,546(4,142)
Comprehensive loss, net of tax, attributable to parent:(253,654)(253,706)(271,450)(353,631)(346,449)(288,144)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: